Literature DB >> 28369303

Transaortic transcatheter aortic valve implantation as a first-line choice or as a last resort? An analysis based on the ROUTE registry.

Nikolaos Bonaros1, Rainer Petzina2, Riccardo Cocchieri3, Dariusz Jagielak4, Marco Aiello5, Joel Lapeze6, Mika Laine7, Sidney Chocron8, Douglas Muir9, Walter Eichinger10, Matthias Thielmann11, Louis Labrousse12, Vinayak Bapat13, Kjell Arne Rein14, Jean-Philippe Verhoye15, Gino Gerosa16, Hardy Baumbach17, Markus Kofler1, Peter Bramlage18, Cornelia Deutsch18, Martin Thoenes19, Derk Frank20, Mauro Romano21.   

Abstract

OBJECTIVES: Transaortic transcatheter aortic valve implantation (TAo-TAVI) is a recently developed alternative to transapical (TA) or transfemoral (TF) TAVI. We aimed to analyse the effectiveness and safety of TAo-TAVI as a first line approach and to compare it to patients receiving TAo-TAVI as a last resort, which is current practice.
METHODS: ROUTE is a prospective, multicentre registry to assess the clinical outcomes of TAo-TAVI. Patients without contraindications for TA- and TF-TAVI (TAo-first) were compared to patients with contraindications for both of these access routes (TAo-last). Outcome analysis was based on VARC II defined clinical end-points.
RESULTS: Three hundred and one patients were included, of which 224 patients met TAo-first and 77 TAo-last criteria. The valve was delivered and catheter retrieved successfully in all patients. In the TAo-first group, rates of conversion to open surgery and requirement for a second valve were low and not different compared to TAo-last patients (1% vs. 3%, P  = 0.46 and 1% vs. 3%, P  = 0.46, respectively). This was also true for the rate of paravalvular regurgitation (≥ moderate: 4% vs. 3%). All-cause mortality at 30-days was 6% vs. 5% ( P  = 0.76), rates of stroke 2% vs. 0% ( P  = 0.24), pacemaker implantation (11% vs. 4%, P  = 0.093), and life-threatening bleeding 4% vs. 3% ( P  = 0.70). Valve safety (both 85%, P  = 0.98) and clinical efficacy (80% vs. 82%; P = 0.73) did not differ between groups.
CONCLUSIONS: Although comparative data to TA and TF procedures were not available in the present analysis, findings suggest that TAo may be considered not only as a last resort strategy when classical access routes are deemed unfeasible, but also as a potential first-line option, with only low rates of paravalvular regurgitation and permanent pacemaker implantation. CLINICALTRIALS.GOV: NCT01991431.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  SAPIEN; TAVI; Transaortic; Transapical; Transcatheter Aortic Valve Implantation; Transfemoral

Mesh:

Year:  2017        PMID: 28369303     DOI: 10.1093/ejcts/ezw406

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

Review 1.  Transcatheter aortic valve replacement with a focus on transcarotid: a review of the current literature.

Authors:  Issa Pour-Ghaz; Joel Raja; Mahmoud Bayoumi; Theodore Manolukas; Rami N Khouzam; Uzoma N Ibebuogu
Journal:  Ann Transl Med       Date:  2019-09

2.  Direct aortic route versus transaxillary route for transcatheter aortic valve replacement: a systematic review and meta-analysis.

Authors:  Hsiu-An Lee; I-Li Su; Shao-Wei Chen; Victor Chien-Chia Wu; Dong-Yi Chen; Pao-Hsien Chu; An-Hsun Chou; Yu-Ting Cheng; Pyng-Jing Lin; Feng-Chun Tsai
Journal:  PeerJ       Date:  2020-05-12       Impact factor: 2.984

3.  Health-related quality of life following transcatheter aortic valve implantation using transaortic, transfemoral approaches and surgical aortic valve replacement-a single-center study.

Authors:  Aleksandra Stańska; Dariusz Jagielak; Maciej Kowalik; Maciej Brzeziński; Rafał Pawlaczyk; Jadwiga Fijałkowska; Wojciech Karolak; Jan Rogowski; Peter Bramlage
Journal:  J Geriatr Cardiol       Date:  2018-11       Impact factor: 3.327

4.  Trial protocol for the validation of the 'Toronto Aortic Stenosis Quality of Life (TASQ) Questionnaire' in patients undergoing surgical aortic valve replacement (SAVR) or transfemoral (TF) transcatheter aortic valve implantation (TAVI): the TASQ registry.

Authors:  Derk Frank; Simon Kennon; Nikolaos Bonaros; Mauro Romano; Thierry Lefèvre; Carlo Di Mario; Pierluigi Stefàno; Flavio Luciano Ribichini; Dominique Himbert; Marina Urena-Alcazar; Jorge Salgado-Fernandez; Jose Joaquin Cuenca Castillo; Bruno Garcia; Jana Kurucova; Martin Thoenes; Claudia Lüske; Peter Bramlage; Rima Styra
Journal:  Open Heart       Date:  2019-05-21

Review 5.  Minireview: Transaortic Transcatheter Aortic Valve Implantation: Is There Still an Indication?

Authors:  Lukas Stastny; Christoph Krapf; Julia Dumfarth; Simone Gasser; Axel Bauer; Guy Friedrich; Bernhard Metzler; Gudrun Feuchtner; Agnes Mayr; Michael Grimm; Nikolaos Bonaros
Journal:  Front Cardiovasc Med       Date:  2022-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.